Association of XRCC2 rs3218536 Polymorphism with Susceptibility of Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis

Kamali, Mahdieh; Hamadani, Sedigheh; Neamatzadeh, Hossein; Mazaheri, Mahta; Zare-Shehneh, Masoud; Modaress Gilani, Mitra; Haghighi, Fatemeh

doi:10.22034/APJCP.2017.18.7.1743

Association of XRCC2 rs3218536 Polymorphism with Susceptibility of Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis

Document Type : Systematic Review and Meta-analysis

Authors

¹ Department of Perinatology, School of Medicine, Tehran University Medical of Sciences, Tehran, Iran.

² Maternal-Fetal and Neonatal Research Center, Tehran University of Medical Sciences, Tehran, Iran.

³ Mother and Newborn Health Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

⁴ Department of Medical Genetics, International Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

⁵ Department of Gynecology and Obstetrics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

10.22034/APJCP.2017.18.7.1743

Abstract

Background: Previous studies have investigated the association of X-Ray Repair Cross-Complementing Group 2 (XRCC2) rs3218536 polymorphism with breast and ovarian cancer. However, this association remains conflicting. Therefore, we have performed the current systematic review and meta-analysis to clarify the association between XRCC2 rs3218536 polymorphism with risk of breast and ovarian cancer. Methods: We conducted a search in PubMed, Google Scholar and ISI Web of Science to select relevant studies on the association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer susceptibility. We calculated the odds ratios (OR) and 95% confidence intervals (CI) for five genetic contrasts. In addition, a stratified analysis was conducted cancer type, ethnicity and HWE status. Results: A total of 17 studies with 5694 cases and 6450 controls for breast cancer and nine case-control studies with 4464 cases and 6353 controls for ovarian cancer were identified for the analysis of the association with XRCC2 rs3218536 polymorphism. The pooled ORs revealed that XRCC2 rs3218536 polymorphism was associated with breast cancer under the heterozygote contrast (AG vs. GG: OR = 0.929, 95% CI = 0.873-0.987, p=0.018) and ovarian cancer under dominant contrast (AA+AG vs. GG: OR = 0.725, 95% CI = 0.537-0.979, p=0.036) in the overall population. The stratified analysis indicated a significant association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer risk among Caucasians. Conclusion: Inconsistent with previous meta-analysis, this meta-analysis shows that the XRCC2 rs3218536 polymorphism was associated with breast and ovarian cancer risk in overall population, especially among Caucasians.

Keywords